Recent studies have also reviewed the involvement of NRF2 in the activation of multidrug resistance proteins [72], in particular to modulate the expression of efflux transporters, of phase II metabolic enzymes [64], and of antiapoptotic genes (Bcl-2) [73,74], thus supporting the chemoresistance ability of cancer cells. This evidence concerns the gene NFE2L2 and cancer.